Objectives: Recent studies have suggested that longterm diuretic therapy may be associated with increased risk of renal cell carcinoma. This carcinoma is not a common malignancy, but it shares risk factors with the considerably more widespread colon cancer (CC). However, there are no data whether or not a relationship between long-term diuretic therapy and CC mortality exists. In this study we tested the hypothesis that longterm diuretic therapy may be associated with increased CC mortality over a 5.6-year follow-up period. Subjects and methods: The study sample comprised 14 166 patients aged 45 to 74 years with a previous myocardial infarction and/or stable anginal syndrome, screened for participation in the bezafibrate infarction prevention (BIP) study. There were 2153 patients receiving diuretics and 12 013 patients receiving no diuretics. Results: During the follow-up 139 (6.5%) new cases of cancer were diagnosed in the diuretic-treated group compared with 622 (5.2%) in the group receiving no
Introduction
Several recent large studies have suggested that long-term diuretic therapy may be associated with increased risk for development of renal cell carcinoma. [1] [2] [3] [4] [5] [6] Recent reports have provided new insights regarding the importance of colon epithelium as a part of the osmoregulatory system working under the control of aldosterone and antidiuretic hormone. 7, 8 In particular, sodium transport via amiloride sensitive channels of both colon and renal tubule epithelia plays a noticeable role in homeostasis.
One of the explanations for the link between renal cell carcinoma and diuretic treatment is the fact that renal cancer originates from renal tubular cells, which are the primary target of the diuretic's pharmacological effect. 11 It is possible that chemical influences on these cells over time may have slight carcinogenic effect and the duration of the diuretic therapy may be related to the risk of renal cancer.
Recently, we reported data regarding conceivable association between long-term diuretic therapy and colon cancer (CC) incidence. 12 However, in contrast to renal cancer, there are no data whether or not a relationship between long-term diuretic therapy and CC mortality exists. In this study we tested the hypothesis that long-term diuretic therapy may be associated with increased CC mortality.
Materials and methods

Subjects
The initial study sample comprised 15 524 patients aged between 45 and 74 years with a previous myocardial infarction (0.5 to 5 years prior to commencement of follow-up) and/or stable anginal syndrome (within 2 years preceding the examination), screened for participation for bezafibrate infarction prevention (BIP) study. 13 The BIP study was designed and initiated in 1990. There was no difference in the distribution of all-cause and cardiac mortality between the bezafibrate and placebo study groups. 14 The major inclusion and exclusion criteria for the BIP study, as well as the ethical guidelines, have been previously reported. 13, 14 In brief, between 1 February 1990, and 30 October 1992 all patients underwent a complete medical examination and biochemical blood tests; historical, medical, and drug intake data were recorded. The major exclusion criteria for the BIP study were: permanent pacemaker implantation, cerebrovascular disease, chronic hepatic or renal disease, peripheral vascular disease, malignant diseases, estrogen replacement therapy and insulin dependent diabetes mellitus.
Laboratory methods
Cooled blood samples, collected in the 18 participating centres using standard equipment and procedures, were transferred to the study's central laboratory. All analyses were performed on a Boehringer Hitachi 704 random access analyser using Boehringer diagnostic kits. Detailed data on laboratory methods are given in a previous report. 14 Briefly, glucose values were determined by the GOD-PAPP method, employing a BM/Hitachi 717/911 analyser. Evaluation of triglycerides was performed by determination of total values (GPO-PAP high performance method). High-density lipoprotein (HDL) cholesterol was measured by precipitation of low and very low-density lipoproteins with phosphotungstate reagent and determination of cholesterol by the CHOD-PAP method.
Follow-up period for cancer incidence and mortality registration lasted to December 1996 (mean 5.6 ± 0.8, range 4 to 7 years).
Mortality and cancer incidence data were obtained by matching the patients' identification numbers with their life status respectively in the Israel Population Registry and National Cancer Registry. Each matched record was checked for correct identification.
Death certificates were coded using the system described in the ninth edition of the International Classification of Disease (ICD-9CM), in which cancer is denoted by codes 140 to 208 and 230-239 and ischaemic heart disease (IHD) is denoted by codes 410 to 414. 15 Because vital status could not be verified in 827 cases at the end of follow-up, they were excluded from the present analysis, as well as patients in whom a diagnosis of cancer was made prior to the BIP screening visit (n ϭ 531). Therefore, the final study sample comprised 14 166 patients.
Statistical analysis
Data were analysed using SAS software. 16 Continuous variables were presented as mean value ± standard deviation (s.d.). Comparisons between groups were made using chi-square tests for discrete variables and Student t-test for continuous variables. Age adjusted mortality rates per 1000 person years were computed using a special SAS macro. 17 The log-rank test was used for comparing the curves. Multivariate analysis of cancer incidence and mortality was performed using the stepwise Cox proportional hazard model (PHREG procedure) to account for differing lengths of follow-up and correlation with covariates. 18 Because of skewed distribution of triglyceride levels, a natural log was used in the models. The significance levels for entering and removing an explnatory variable were set at 0.05.
Results
Baseline data
Out of 14 166 patients, 2153 were on diuretics and 12 013 patients receiving no diuretic drugs. The clinical and laboratory characteristics of the patients are presented in Table 1 . In general, diuretic-treated patients were older, had unfavourable cardiovascular risk-factors background and a higher incidence of chronic diseases. The majority of the patients in both groups were men, had sustained a previous myocardial infarction and most had a history of anginal syndrome. As expected, the proportion of patients with elevated blood pressure and heart failure (New York Heart Association (NYHA) functional classification у2) was significantly higher in the diuretic-treated group. The degree of metabolic abnormalities (mean fasting blood glucose, cholesterol and triglyceride levels) was more prominent in the diuretic-treated group. The data regarding treatment with cardiovascular drugs among the study groups are presented in Table 2 . Nitrates, calcium antagonists, beta-blockers and antiplatelet drugs were administered frequently; as expected, more diuretic-treated patients received ACE-inhibitors, potassium, digitalis and nitrates than their normotensive counterparts. Beta-blockers and aspirin were administered more frequently in patients receiving no diuretics: beta-blockers in 4439 (37%) vs 574 (27%) of patients and aspirin in 6794 (57%) vs 932 (43%) of them.
Cancer incidence
Patients were followed from 4 to 7 years (mean 5.6 ± 0.8 years). The incidence of main cancer types is presented in Table 3 . In both groups the digestive, Journal of Human Hypertension genitourinary and respiratory systems were the most frequently involved. During the follow-up 139 (6.5%) new cases of cancer were diagnosed in the diuretic-treated group compared with 622 (5.2%) in the group without diuretics (P ϭ 0.02).
As we have previously reported, 12 the crude incidence of colon and kidney cancers only was higher in the diuretic-treated group (respectively 0.6 vs 1.1%, P ϭ 0.02 and 0.25 vs 0.5%, P ϭ 0.08). The association between diuretic therapy and higher incidence of colon cancer was augmented among non-users of aspirin (17 (1.39%) of 1204 patients on diuretics vs 31 (0.59%) of 5188 patients without diuretics, P ϭ 0.004), whereas among aspirin users an equal colon cancer incidence was observed regardless the presence or absence of diuretic therapy (6 (0.64%) of 926 patients on diuretics vs 42 (0.62%) of 6752 patients without diuretics, P ϭ 0.93). The incidence of lung, prostate and bladder cancers was not significantly different in diuretics users and non-users.
In order to assess whether the association between diuretics and colon cancer incidence persisted in diverse categories of cardiovascular status, ageadjusted colon cancer incidence rate per 100 000 person-years was determined in patients with and without a history of myocardial infarction, smoking, hypertension, and by functional capacity classes according to the NYHA classification ( Table 4 ). The highest colon cancer incidence rates were found in diuretic-treated patients, regardless of the presence or absence of a history of myocardial infarction, smoking, hypertension and heart failure (in accordance with functional NYHA classification classes).
Mortality
Crude all-cause, ischaemic heart disease (IHD) and cancer mortality among the study patients are shown in Table 5 . During the follow-up period, crude all-cause and IHD mortality was lower in the non-diuretic than in the diuretic-treated group (respectively 9.7% vs 24.5%; 4.4% vs 12.0%, P ϭ 0.0001). Colon cancer mortality was significantly higher in the diuretic-treated patients (P ϭ 0.001), whereas mortality differences for other cancer types were not observed.
Multivariate analysis
Multivariate analysis (including age, gender, myocardial infarction, congestive heart failure, hypertension, peripheral vascular disease, cerebrovascular accident, anginal syndrome, diabetes, chronic obstructive pulmonary disease, current and past smoking, inclusion in BIP study, body mass index, HR, hazard ratio adjusted for other significant variables; CI, confidence interval. There were following variables significantly associated with all-cause mortality but not with cancer incidence: diabetes mellitus, heart failure, history of myocardial infarction, cerebro-vascular accident, angina pectoris, peripheral vascudisease, chronic obstructive pulmonary disease, fasting glucose level, heart rate.
heart rate, fasting glucose, cholesterol, triglycerides, angiotensin converting enzyme inhibitors, nitrates, potassium, digitalis and aspirin treatment) identified diuretics as an independent predictor of increased colon cancer incidence and colon cancer mortality with a hazard ratio (HR) of 2.0 (95% CI 1.2-3.2) for colon cancer incidence and 3.7 (95% CI 1.7-8.3) for mortality. The all-types cancer mortality also tended to be higher in the diuretic-treated patients (Table 6 ) with HR of 1.35 (95% CI 0.96-1.80).
Different diuretics and their association with colon cancer incidence
Furosemide, hydrochlorthiazide and amiloride/ hydrochlorthiazide combination were the most prevalent diuretics (Table 7) . A relatively higher colon cancer incidence was observed in the small combined amiloride/hydrochlorthiazide subgroup (HR 3.15, 95% CI 1.15-8.65).
Discussion
The main finding of our study was the association between diuretic therapy and increased colon cancer incidence and mortality. However, the association between diuretic therapy and higher incidence of colon cancer was observed only among non-users of aspirin. A large number of epidemiological studies have explored the relation between environmental factors (mainly diet and physical activity) and risk for colon cancer. Some data suggest that folate deficiency, high intake of alcohol and overconsumption of food increase the risk, whereas antioxidants in general, nonsteroid anti-inflammatory drugs-including aspirin-and folate intake may be protective. [19] [20] [21] [22] [23] [24] [25] Colon cancer is a classical example of multifactorial carcinogenesis. There is strong evidence that molecular genetic changes are associated with colon cancer. Two identified tumor associated genes, DCC 377 Table 7 Distribution of different diuretics among study patients (number and percentage) and their association with cancer incidence (all types and colon) Table 6 ); CI, confidence interval. *Using patients without diuretics as a reference group.
(deleted in colon carcinoma) and MCC (mutated in colon carcinoma), contribute to the multistep transformation from normal colonic mucosa to carcinoma. Moreover, mutations in some other genes (p53, k-ras, APC) are involved in the development of colorectal cancer. 19, 26, 27 The present report confirms the data from several large recent studies regarding possible association between long-term diuretic therapy and increased risk for renal cell carcinoma. [1] [2] [3] [4] [5] [6] 11 This carcinoma shares risk factors with considerably more widespread cancer of colon. Significant persisting correlations were observed between renal cell and colon carcinomas suggesting a role of mutual carcinogenic mechanisms. 28 There are a number of controversial publications regarding potential toxic, mutagenic and carcinogenic effects of different diuretic agents. Chronic high doses furosemide administration in rats and mice was associated with development of nephropathy and malignant tumors of mammary glands in female. Marginal increases in tubular cell neoplasms of the kidney and in meningiomas of the brain were observed as well. 29 Chronic high doses hydrochlorthiazide administration in rats led to severe chronic renal disease with secondary parathyroid hyperplasia and fibrous osteodystrophy of the bone. [30] [31] [32] In high-dose hydrochlorthiazide treated male mice, liver neoplasms were increased but were not considered to be related to hydrochlorthiazide because of an unusually low incidence in the control group relative to historical controls. 32 One hypothetical mechanism suggests that hydrochlorthiazide as a cyclic imide can be converted in the stomach to a mutagenic nitroso derivative. 33, 34 A recent small study 35 have shown that in hypertensive patients chronic diuretic use is associated with a significant decrease in red blood cell foliate concentration (and increase in serum homocysteine concentration). Triamterene-a potassium-sparing agent widely used alone or in combination with other diuretics, which had been found to be positive for mutagenicity and antifolate activity in several in vitro (but not in vivo) assays. 36, 37 The results of some studies do not support the hypothesis that use of diuretic medication increases renal cell carcinoma risk; they are more consistent with an association between renal cell
Journal of Human Hypertension carcinoma and high blood pressure. 38, 39 The principal role of renal tubule and cortical collecting duct epithelia in electrolytes and pH homeostasis is well known. Recent studies have provided new insights regarding important function of colon epithelium as a part of the osmoregulatory system working under the control of aldosterone and antidiuretic hormone. In particular, sodium transport via amiloride sensitive channels of both colon and renal tubule epithelia has a noticeable role in homeostasis. It is important, that colon cancer originates from colon epitheliums, which may be the target of the diuretic's pharmacological effect, similar to that upon renal tubular cells. It is possible that cumulative chemical influences on these cells for years may have a slight carcinogenic effect and duration of diuretic therapy may be related to the risk of renal and colon cancer.
In patients with heart failure the diuretic therapy often has life-saving features; however the overall benefits of diuretics in mild hypertension are modest. 40 The potential low-grade carcinogenic of these agents may be negligible in the congestive heart failure and/or elderly hypertensive patients due to their relatively short life expectancy, but should be taken into account in the young and middle-aged patients which may be exposed to antihypertensive therapy for decades. This point acquires special relevance when two diuretic preparations are simultaneously used over a prolonged period. A substantially timerelated increased incidence of colon cancer was observed among patients on combined (amiloride/ hydrochlorthiazide) diuretic treatment over a 5.6-year follow-up. However, the relative small number of patients on combined diuretic treatment and the wide confidence interval require caution when drawing conclusions regarding this observation.
Two large recent important clinical trials, the Systolic Hypertension in the Elderly Program (SHEP) and the Systolic Hypertension in Europe (Syst-Eur) trial have confirmed that reducing of systolic blood pressure in the elderly reduced morbidity and mortality. 41, 42 The reports of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC-VI) recommend beta-blockers and diuretics as first-line therapy for uncomplicated essential hypertension. 43 In general, diuretics in the elderly have been superior to beta-blockers with regard to all end points (mortality and cardiovascular events). 44 However in the light of their possible low-grade carcinogenity the use of diuretics as initial antihypertensive therapy in the young and middle-aged patients should be investigated.
Study limitations
This is a retrospective observational study; information on drug doses was not available. Therefore, caution ought to be used in interpreting our findings since it may be difficult, even in multivariate analysis, to distinguish between undesirable drug effects and those related to the degree of metabolic abnormalities. In general, diuretic-treated patients were older, had an unfavourable cardiovascular riskfactor background and more chronic diseases. One might presume that physical activity was less prevalent among the diuretic users. Aspirin (which may be protective against colon cancer 24, 25 was administered more frequently in patients receiving no diuretics. The degree of metabolic abnormalities (mean blood fasting glucose, cholesterol and triglyceride levels) was more prominent in the diuretictreated group. Since the diuretics were not randomly distributed between the two groups, one might presume that the diuretic use did not increase colon cancer incidence by itself but in associations with other factors. The association between diuretic therapy and higher incidence of colon cancer was found only among the non-users of aspirin. Data regarding other nonsteroidal anti-inflammatory agents were not available.
Conclusion
Long-term exposure to diuretic therapy may be associated with an increased colon cancer-related mortality.
